These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3435 related articles for article (PubMed ID: 7332319)

  • 1. Interactions of the third component of human complement (C3) with tumour cells: evidence for presence of C3b acceptor sites and direct activation of C3 by tumour cells.
    Daveau M; Fontaine M; Gilbert D
    Ann Immunol (Paris); 1981; 132C(3):339-50. PubMed ID: 7332319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative pathway of complement activation by stimulated T lymphocytes. I. Binding of C3 fragments.
    Sármay G; Ramos OF; Klein E; Kai C; Gergely J
    Eur J Immunol; 1987 Jul; 17(7):969-74. PubMed ID: 3111862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus regulates activation and processing of the third component of complement.
    Mold C; Bradt BM; Nemerow GR; Cooper NR
    J Exp Med; 1988 Sep; 168(3):949-69. PubMed ID: 2844953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.
    Kozel TR; Pfrommer GS
    Infect Immun; 1986 Apr; 52(1):1-5. PubMed ID: 3514450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3.
    Pangburn MK; Müller-Eberhard HJ
    Ann N Y Acad Sci; 1983; 421():291-8. PubMed ID: 6586103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B.
    Joiner K; Sher A; Gaither T; Hammer C
    Proc Natl Acad Sci U S A; 1986 Sep; 83(17):6593-7. PubMed ID: 2944112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor for soluble C3 and C3b on human lymphoblastoid (RAJI) cells. Properties and biologocal significance.
    Theofilopoulos AN; Bokisch VA; Dixon FJ
    J Exp Med; 1974 Mar; 139(3):696-711. PubMed ID: 4591176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb.
    Leijh PC; van den Barselaar MT; Daha MR; van Furth R
    J Immunol; 1982 Jul; 129(1):332-7. PubMed ID: 6979568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for three binding sites for C3 (hemolytically inactive), C3b and C3d on a CR2-positive Burkitt lymphoma-derived cell line (Raji).
    Barile G; Di Renzo L; Lipari M; Frati L; Faggioni A
    FEBS Lett; 1993 Jun; 324(3):319-24. PubMed ID: 8405374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attachment of [35S]cysteine to the labile site of the third component of complement via the alternative pathway.
    Rutherford CJ; Alper CA; Rosen FS; Babior BM
    Clin Immunol Immunopathol; 1983 Jan; 26(1):76-82. PubMed ID: 6872338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-binding sites on C3 and C3b.
    Dierich MP; Bokisch VA
    J Immunol; 1977 Jun; 118(6):2145-50. PubMed ID: 864256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of neutrophil expression of C3b receptors (CR1) by soluble monomeric human C3b.
    Porteu F; Mir A; Halbwachs-Mecarelli L
    Eur J Immunol; 1987 May; 17(5):629-35. PubMed ID: 2953614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism.
    Theofilopoulos AN; Dixon FJ; Bokisch VA
    J Exp Med; 1974 Oct; 140(4):877-94. PubMed ID: 4139225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 172.